Allergy Injection Reactions Across All Injectable Immunotherapy Types

Venom immunotherapy (VIT) for Hymenoptera sting allergy carries a systemic reaction rate of 5-15% per patient during build-up — significantly higher than the 0.1-0.2% per visit rate for conventional inhalant SCIT. The higher rate reflects several factors: patients receiving VIT have already demonstrated severe IgE-mediated reactivity to venom proteins, establishing high baseline sensitization; the target maintenance dose of 100 micrograms venom protein is pharmacologically active and provokes measurable immune responses; and venom proteins (phospholipase A2, hyaluronidase) are highly potent allergens with well-documented mast cell activation capacity. Despite the higher reaction rate during build-up, maintenance VIT provides 98% protection against future sting anaphylaxis (Golden 2005), making the risk-benefit ratio strongly favorable for patients with confirmed Hymenoptera venom allergy.

Cluster allergy shot build-up delivers 2-4 injections per clinic visit on an accelerated schedule, reaching the maintenance dose in 4-8 weeks instead of the conventional 3-6 months. The trade-off for faster progression is a significantly higher per-injection systemic reaction rate. Tversky et al. (JACI 2022; Johns Hopkins, n=91) quantified this at 2.29% per injection for cluster versus 0.69% for conventional build-up — an incidence rate ratio of 3.3 (95% CI 1.5-7.3). A multicenter cluster cohort reported 10.9% per-patient systemic reaction rates with Grade 4 anaphylaxis in 2% of patients. Cluster protocols require antihistamine premedication, vital-signs checks before each within-visit dose, 30-minute observation between same-day injections, and extended post-final-injection observation. Cluster is typically reserved for patients who cannot commit to conventional weekly build-up schedules.

Intralymphatic immunotherapy (ILIT) is an experimental protocol delivering allergen extract directly into inguinal lymph nodes under ultrasound guidance, typically as 3 injections spaced 4 weeks apart. The rationale is that lymph node delivery achieves desensitization with a fraction of the cumulative dose needed for subcutaneous immunotherapy. Senti et al. (PNAS 2008) conducted the landmark proof-of-concept trial. The distinctive adverse event of ILIT is local lymph node swelling in approximately 20% of patients, reflecting the immune response at the delivery site — different in character from the injection-site erythema seen with conventional SCIT. Systemic reactions with ILIT are rare given the very small allergen doses used. ILIT is not currently FDA-approved in the United States and remains investigational, available primarily in European research settings.

Premedication significantly reduces but does not eliminate systemic reactions, and its effectiveness varies by protocol. For rush immunotherapy, Portnoy (Ann Allergy 1994) demonstrated 27% systemic reaction rate with premedication versus 73% without — a substantial benefit. For cluster protocols, H1 plus H2 antihistamine plus leukotriene antagonist combinations have shown reduction in systemic reaction rates in multiple cohorts. For conventional build-up, premedication is not strongly supported by evidence: it reduces large local reaction frequency but may mask early cutaneous warning signs of progressing systemic reactions, potentially delaying intervention. The AAAAI/ACAAI Practice Parameter does not recommend routine antihistamine premedication for conventional SCIT. For venom immunotherapy build-up, premedication with fexofenadine or cetirizine is common practice, and omalizumab co-administration reduces rush VIT reaction rates by approximately 80% (Casale et al., JACI 2006).

A biphasic anaphylactic reaction is a recurrence of anaphylaxis after apparent complete resolution of the initial episode, without additional allergen exposure. In SCIT and other injectable immunotherapy contexts, biphasic reactions can occur 1-72 hours after the initial event, most commonly at 4-10 hours. The incidence of biphasic reactions across all anaphylaxis settings (not SCIT-specific) ranges from 1-20% of anaphylactic events, with most estimates in the 5-20% range. SCIT surveillance literature does not separately report biphasic versus delayed systemic reactions, so the biphasic incidence specifically for SCIT anaphylaxis is not precisely quantified. The practical implication is that patients who experience Grade 3-4 systemic reactions during SCIT should be observed for a minimum of 4-8 hours — not just the standard 30 minutes — and should not be discharged without arrangements for monitoring if late recurrence occurs.

Yes, omalizumab (Xolair) pretreatment before rush SCIT has demonstrated meaningful reduction in systemic reaction rates. Casale et al. (JACI 2006) randomized patients undergoing rush cat allergen immunotherapy to omalizumab or placebo pretreatment: omalizumab reduced the systemic reaction rate during rush build-up by approximately 80%. The mechanism is omalizumab's anti-IgE activity — by binding free IgE and reducing FcepsilonRI expression on mast cells and basophils, omalizumab decreases the mast cell reactivity that drives anaphylactic responses. This approach is particularly relevant for patients with high baseline specific IgE, unstable asthma, or prior systemic reactions who would otherwise be considered too high-risk for accelerated protocols. Omalizumab pretreatment has also been studied as a way to allow continued immunotherapy in patients with mast cell disorders or recurrent systemic reactions despite dose modification.

The fundamental reaction profiles of allergy injection modalities are similar in children and adults, but several factors differ in practice. Children generally have lower rates of severe systemic reactions per injection compared to adults in some surveillance analyses, possibly reflecting differences in comorbidity burden — particularly lower rates of uncontrolled asthma and beta-blocker use, which are the dominant adult risk factors. A pediatric cohort (Bahceci Erdem 2021) found a 3.32-fold increased systemic reaction risk after large local reactions, with 95% CI 1.31-8.44, suggesting the LLR-as-predictor signal may be more meaningful in pediatric populations than in adults. Venom immunotherapy in children carries the same life-saving indication as in adults. EAACI guidelines and U.S. practice parameters endorse SCIT from age 5 years in appropriate candidates, with the same post-injection observation requirements as adult patients.